Haemonetics Corporation (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $95.00.

Several research firms recently issued reports on HAE. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $72.00 to $80.00 in a research report on Friday, May 22nd. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Barrington Research boosted their price target on Haemonetics from $95.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday. Mizuho upped their price target on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a report on Friday, August 7th.

Haemonetics Stock Up 3.6%

NYSE:HAE opened at $108.39 on Thursday. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The firm has a market cap of $4.93 billion, a P/E ratio of 53.14, a P/E/G ratio of 2.10 and a beta of 0.52. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $108.50. The firm has a 50-day simple moving average of $80.50 and a two-hundred day simple moving average of $67.90.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. During the same quarter in the prior year, the firm posted $1.10 earnings per share. The business’s revenue was up 5.5% on a year-over-year basis. Analysts predict that Haemonetics will post 5.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its position in Haemonetics by 12.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 211 shares during the period. Quantinno Capital Management LP raised its stake in Haemonetics by 9.0% during the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares during the last quarter. UMB Bank n.a. raised its stake in Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 306 shares during the last quarter. Cardinal Capital Management lifted its holdings in shares of Haemonetics by 1.5% during the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock valued at $1,799,000 after buying an additional 321 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the 4th quarter worth $26,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: New CSL Plasma supply agreement: Haemonetics signed a non-exclusive agreement to supply CSL Plasma’s U.S. collection operations. The deal restores business with a major customer after a prior supply transition weighed on results, potentially improving revenue visibility and supporting the company’s plasma-collection franchise. Haemonetics reconnects with CSL in US plasma collection deal
• Positive Sentiment: Raised fiscal 2027 outlook and solid quarterly results: Haemonetics reported quarterly revenue of $339.4 million, up approximately 5.6% year over year, while adjusted EPS rose to $1.14 and exceeded consensus. Management raised its full-year reported revenue-growth forecast to 5%–8% from 4%–7%, with plasma revenue and adoption of Persona PLUS on the NexSys PCS platform providing momentum. Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook
• Positive Sentiment: Analyst support: BTIG raised its price target from $96 to $110 and maintained a Buy rating, reinforcing bullish momentum. BTIG raises Haemonetics price target

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.